ORIC Oric Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1796280 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-15.2%
TTM EPS YoY15.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.8%
ROA-39.1%
ROIC (approx.)-40.8%
Asset turnover—
Leverage & solvency
Liabilities / assets7.5%
Debt / equity0.00x
Current ratio11.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $109.82M | $114.07M |
| SG&A expense | $33.19M | $28.82M |
| Operating income | -$143.00M | -$142.90M |
| Income tax | $0 | $0 |
| Net income | -$129.47M | -$127.85M |
| EBITDA | -$141.78M | -$141.79M |
| EPS (basic) | -1.47 | -1.83 |
| EPS (diluted) | -1.47 | -1.83 |
| Weighted avg. shares (diluted) | 87.79M | 69.73M |
| Balance sheet | ||
| Cash & equivalents | $45.67M | $59.90M |
| Short-term investments | $235.82M | $196.55M |
| Current assets | $288.47M | $262.25M |
| PP&E, net | $2.42M | $2.92M |
| Total assets | $408.89M | $274.14M |
| Current liabilities | $20.42M | $24.85M |
| Total liabilities | $24.53M | $31.02M |
| Shareholders' equity | $384.36M | $243.12M |
| Shares outstanding | 98.53M | 71.02M |
| Cash flow statement | ||
| Operating cash flow | -$110.97M | -$112.66M |
| Capital expenditure | $712,000 | $1.19M |
| Free cash flow | -$111.68M | -$113.85M |
| Investing cash flow | -$148.03M | $22.14M |
| Financing cash flow | $245.26M | $126.55M |
| Depreciation & amortization | $1.22M | $1.11M |
| Stock-based compensation | $25.04M | $20.21M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.